Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tulisokibart in moderately to severely active ulcerative colitis
2025-523766-25-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 45
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing tulisokibart with placebo (2 arms). Primary endpoints: Percentage of participants achieving clinical remission per modified Mayo score at Week 12 and Percentage of participants achieving clinical remission per modified Mayo score at Week 52. Planned start Jun 2024; status: withdrawn.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-523766-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523766-25-00.